Online Appendices
Assigned by a computer generated randomisation schedule Matching placebos, Double blind trial, Central pharmacy held the code and the information was not shared with physicians or patients until the completion of the protocol, Unclear who had access to lipid measurements during study protocol, Flushing was almost universally seen in the drug group Events were assessed for by a standardised questionnaire and an independent blinded end point committee adjudicated all serious events 7% treatment group withdrew from the study and 10% in the placebo group.
Industry funded the study but the sponsor had no role in the collection, analysis or interpretation of the data or in the decision to submit the study for publication. States that reported secondary outcomes will include NSTEMI and STEMI but in results only comments about STEMI data
Aim High 6
Randomly assigned 1:1 ratio. Stratified by history of diabetes and clinical site Assignment was performed with the use of a secure internet connection which provided a randomisation assignment as a numbered drug kit blinded to treatment/placebo Matching placebos. Double blind trial. Placebo contained a small amount of trial drug with the aim of masking the identity of the blinded treatment to patients and study personnel. Only LDL results were reported to clinical sites personnel.
A clinical events committee reviewed suspected events with supporting documentation that did not reveal the treatment assignments Trial terminated early due to increased endpoints in the treatment group. 25.4% of treatment group discontinued allocated therapy and 20.1% of placebo group discontinued allocated therapy. 6.1% discontinued in treatment group due to flushing and 2.5% in placebo group because of flushing Industry funded the study but had no role in the oversight or design of the study or in the analysis or interpretation of the data Arbiter 2 7 Randomly assigned 1:1 ratio Randomisation performed with a computer generated sequence of random numbers, participants were assigned a unique study identification that was used by a central research pharmacy to dispense the study medicine Matching placebo, Double blind trial, Only the research pharmacist was aware of drug assignment. Measurements of lipid levels were made at the start and end of the trial only. 69.2% of treatment group reported flushing and only 12.7% in the placebo group Unclear how events were adjudicated 10.3% of treatment group discontinued allocated therapy and 11.25% of placebo group discontinued allocated therapy Single centre study. Sponsorship was utilised from industry but the study was investigator initiated and the trial database and analysis was performed by investigating institution 
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